Stem definition | Drug id | CAS RN |
---|---|---|
diuretics, chlorothiazide derivatives | 2733 | 133-67-5 |
Dose | Unit | Route |
---|---|---|
4 | mg | O |
4 | mg | O |
Property | Value | Reference |
---|---|---|
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.18 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 60 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
March 9, 1960 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Vital capacity decreased | 151.94 | 33.14 | 27 | 1881 | 929 | 50602287 |
Reversible airways obstruction | 150.19 | 33.14 | 27 | 1881 | 993 | 50602223 |
Sputum culture positive | 141.39 | 33.14 | 27 | 1881 | 1387 | 50601829 |
Bronchial secretion retention | 139.56 | 33.14 | 27 | 1881 | 1486 | 50601730 |
Eosinophil count increased | 96.63 | 33.14 | 28 | 1880 | 8802 | 50594414 |
Multiple allergies | 93.34 | 33.14 | 27 | 1881 | 8436 | 50594780 |
Upper-airway cough syndrome | 93.06 | 33.14 | 27 | 1881 | 8523 | 50594693 |
Obstructive airways disorder | 88.68 | 33.14 | 30 | 1878 | 15622 | 50587594 |
Pulmonary mass | 72.30 | 33.14 | 27 | 1881 | 18678 | 50584538 |
Full blood count abnormal | 66.45 | 33.14 | 27 | 1881 | 23361 | 50579855 |
Renal impairment | 63.57 | 33.14 | 38 | 1870 | 75623 | 50527593 |
Cardiac failure | 60.81 | 33.14 | 37 | 1871 | 76003 | 50527213 |
Respiratory tract infection | 58.29 | 33.14 | 27 | 1881 | 31990 | 50571226 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Renal impairment | 80.57 | 25.24 | 53 | 1664 | 81280 | 29491530 |
Cardiac failure | 58.12 | 25.24 | 43 | 1674 | 79244 | 29493566 |
Hepatic function abnormal | 55.08 | 25.24 | 32 | 1685 | 39227 | 29533583 |
Shoshin beriberi | 44.60 | 25.24 | 7 | 1710 | 69 | 29572741 |
Cerebral infarction | 39.65 | 25.24 | 22 | 1695 | 24653 | 29548157 |
Renal ischaemia | 30.94 | 25.24 | 7 | 1710 | 530 | 29572280 |
Interstitial lung disease | 30.77 | 25.24 | 26 | 1691 | 57692 | 29515118 |
Vitamin B1 deficiency | 29.87 | 25.24 | 6 | 1711 | 257 | 29572553 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Renal impairment | 131.41 | 24.33 | 88 | 3755 | 134929 | 64359960 |
Vital capacity decreased | 124.39 | 24.33 | 25 | 3818 | 1047 | 64493842 |
Reversible airways obstruction | 122.90 | 24.33 | 25 | 3818 | 1113 | 64493776 |
Cardiac failure | 111.58 | 24.33 | 79 | 3764 | 132294 | 64362595 |
Bronchial secretion retention | 103.04 | 24.33 | 25 | 3818 | 2502 | 64492387 |
Sputum culture positive | 98.56 | 24.33 | 25 | 3818 | 3001 | 64491888 |
Multiple allergies | 82.40 | 24.33 | 25 | 3818 | 5789 | 64489100 |
Hepatic function abnormal | 72.39 | 24.33 | 46 | 3797 | 64267 | 64430622 |
Upper-airway cough syndrome | 72.30 | 24.33 | 25 | 3818 | 8745 | 64486144 |
Eosinophil count increased | 71.09 | 24.33 | 28 | 3815 | 14084 | 64480805 |
Obstructive airways disorder | 60.76 | 24.33 | 29 | 3814 | 23156 | 64471733 |
Cerebral infarction | 55.44 | 24.33 | 33 | 3810 | 41011 | 64453878 |
Pulmonary mass | 53.83 | 24.33 | 27 | 3816 | 23989 | 64470900 |
Respiratory tract infection | 45.18 | 24.33 | 28 | 3815 | 37379 | 64457510 |
Shoshin beriberi | 44.41 | 24.33 | 7 | 3836 | 69 | 64494820 |
Full blood count abnormal | 43.00 | 24.33 | 25 | 3818 | 29732 | 64465157 |
Hyperuricaemia | 40.29 | 24.33 | 17 | 3826 | 10174 | 64484715 |
Interstitial lung disease | 39.24 | 24.33 | 38 | 3805 | 97694 | 64397195 |
Fatigue | 31.18 | 24.33 | 4 | 3839 | 748726 | 63746163 |
Platelet count decreased | 29.89 | 24.33 | 43 | 3800 | 167668 | 64327221 |
Decreased appetite | 28.52 | 24.33 | 56 | 3787 | 281233 | 64213656 |
Right ventricular failure | 28.29 | 24.33 | 17 | 3826 | 21454 | 64473435 |
Renal ischaemia | 25.88 | 24.33 | 7 | 3836 | 1076 | 64493813 |
Vitamin B1 deficiency | 24.98 | 24.33 | 6 | 3837 | 574 | 64494315 |
Upper respiratory tract inflammation | 24.42 | 24.33 | 9 | 3834 | 3773 | 64491116 |
None
Source | Code | Description |
---|---|---|
ATC | C03AA06 | CARDIOVASCULAR SYSTEM DIURETICS LOW-CEILING DIURETICS, THIAZIDES Thiazides, plain |
ATC | C03AB06 | CARDIOVASCULAR SYSTEM DIURETICS LOW-CEILING DIURETICS, THIAZIDES Thiazides and potassium in combination |
ATC | C03EA02 | CARDIOVASCULAR SYSTEM DIURETICS DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION Low-ceiling diuretics and potassium-sparing agents |
CHEBI has role | CHEBI:35498 | diuretics |
CHEBI has role | CHEBI:35674 | antihypertensive drugs |
MeSH PA | D000959 | Antihypertensive Agents |
MeSH PA | D002317 | Cardiovascular Agents |
MeSH PA | D004232 | Diuretics |
MeSH PA | D049990 | Membrane Transport Modulators |
MeSH PA | D045283 | Natriuretic Agents |
MeSH PA | D049993 | Sodium Chloride Symporter Inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Hypertensive disorder | indication | 38341003 | DOID:10763 |
Suicidal thoughts | contraindication | 6471006 | |
Peptic ulcer | contraindication | 13200003 | DOID:750 |
Chronic disease of respiratory system | contraindication | 17097001 | |
Electroconvulsive therapy | contraindication | 23835007 | |
Depressive disorder | contraindication | 35489007 | |
Conduction disorder of the heart | contraindication | 44808001 | |
Chronic heart failure | contraindication | 48447003 | |
Ulcerative colitis | contraindication | 64766004 | DOID:8577 |
Epilepsy | contraindication | 84757009 | DOID:1826 |
Kidney disease | contraindication | 90708001 | DOID:557 |
Calculus in biliary tract | contraindication | 266474003 |
Species | Use | Relation |
---|---|---|
Cattle | No Use Class Stated Or Implied | Indication |
Product | Applicant | Ingredients |
---|---|---|
Naquasone Bolus | Intervet Inc. | 2 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 7.05 | acidic |
pKa2 | 10.3 | acidic |
pKa3 | 1.29 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Solute carrier family 12 member 3 | Transporter | INHIBITOR | A2 | 7 | WOMBAT-PK | CHEMBL | |||
Carbonic anhydrase 1 | Enzyme | Ki | 6.46 | CHEMBL | |||||
Carbonic anhydrase 4 | Enzyme | Ki | 6.35 | CHEMBL | |||||
Carbonic anhydrase 9 | Enzyme | Ki | 7.06 | CHEMBL | |||||
Carbonic anhydrase 12 | Enzyme | Ki | 6.51 | CHEMBL | |||||
Carbonic anhydrase 5A, mitochondrial | Enzyme | Ki | 6.12 | CHEMBL | |||||
Carbonic anhydrase 5B, mitochondrial | Enzyme | Ki | 6.87 | CHEMBL | |||||
Carbonic anhydrase 7 | Enzyme | Ki | 8.10 | CHEMBL | |||||
Carbonic anhydrase 6 | Enzyme | Ki | 5.61 | CHEMBL | |||||
Carbonic anhydrase 14 | Enzyme | Ki | 5.46 | CHEMBL | |||||
Carbonic anhydrase 2 | Enzyme | Ki | 7.04 | CHEMBL | |||||
Carbonic anhydrase 13 | Enzyme | Ki | 6.19 | CHEMBL |
ID | Source |
---|---|
4018612 | VUID |
N0000146925 | NUI |
D00658 | KEGG_DRUG |
4018612 | VANDF |
C0040899 | UMLSCUI |
CHEBI:9683 | CHEBI |
CHEMBL1054 | ChEMBL_ID |
DB01021 | DRUGBANK_ID |
D014237 | MESH_DESCRIPTOR_UI |
5560 | PUBCHEM_CID |
7314 | IUPHAR_LIGAND_ID |
1012 | INN_ID |
Q58C92TUN0 | UNII |
10772 | RXNORM |
3169 | MMSL |
5619 | MMSL |
d00646 | MMSL |
002300 | NDDF |
11473005 | SNOMEDCT_US |
409112007 | SNOMEDCT_US |
None